Xencor Inc
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Xencor Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 9.30 $ to 29.30 $ · Last price: 24.60 $ (As of: September 17, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/18/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Biotechnology
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Xencor Inc XNCR | 1.8 | – | -17.3 | -143.7 | – | 13.7 | 165.8 |
| Vertex Pharmaceuticals Inc VRTX | 130.6 | 31.3 | 24.5 | 55.0 | 38.1 | 9.6 | 33.4 |
| Regeneron Pharmaceuticals Inc REGN | 82.0 | 19.9 | 13.1 | 44.5 | 20.7 | 1.0 | 35.5 |
| Moderna Inc MRNA | 62.7 | – | 4.6 | -66.0 | -131.1 | -39.2 | 532.3 |
| argenx NV ARGX | 61.9 | 38.1 | 34.2 | 59.1 | 32.0 | 89.6 | 30.9 |
| Revolution Medicines Inc RVMD | 40.9 | – | -9.7 | -174,708.6 | 0.0 | -100.0 | 338.3 |
| BeiGene, Ltd. ONC | 40.0 | 63.1 | 34.1 | 88.9 | 19.1 | 40.2 | 6.4 |
| Alnylam Pharmaceuticals Inc ALNY | 32.6 | 61.8 | 28.4 | 79.7 | 23.0 | 65.2 | -48.1 |
| Royalty Pharma Plc RPRX | 32.5 | 31.8 | 19.6 | 95.8 | 100.3 | 5.1 | 68.6 |
| Median of companies shown | 40.9 | 34.9 | 19.6 | 55.0 | 21.8 | 9.6 | 35.5 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 88 | 23 | 24 | 0.56 | 95 | 314 | 429 |
| 2017 | 36 | -54 | -49 | -1.05 | -34 | 282 | 390 |
| 2018 | 41 | -79 | -70 | -1.31 | -80 | 522 | 577 |
| 2019 | 157 | 14 | 27 | 0.46 | 64 | 593 | 670 |
| 2020 | 123 | -77 | -64 | -1.11 | -5 | 572 | 703 |
| 2021 | 275 | 44 | 83 | 1.37 | -17 | 734 | 838 |
| 2022 | 165 | -82 | -55 | -0.93 | 24 | 728 | 846 |
| 2023 | 168 | -139 | -126 | -2.08 | 85 | 669 | 953 |
| 2024 | 110 | -178 | -233 | -3.58 | -202 | 678 | 952 |
| 2025 | 126 | -178 | -92 | -1.24 | -135 | 636 | 876 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.73 | – | 53 | 3.50 | -76.40 | -56 | -58 |
| 2025: Q1 | -0.66 | – | 33 | 104.60 | -147.90 | -16 | -18 |
| 2025: Q2 | -0.41 | – | 44 | 157.10 | -70.70 | -36 | -37 |
| 2025: Q3 | -0.08 | – | 21 | 18.00 | -28.70 | -31 | -31 |
| 2025: Q4 | -0.09 | – | 28 | -46.60 | -23.60 | -52 | -53 |
| 2026: Q1 | -1.71 | – | 5 | -86.20 | -2,854.70 | -68 | -68 |
| 2026: Q2 | -0.29 | 29.30 | 51 | 17.40 | -42.40 | -56 | -56 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 4 of our scanner strategies — each hit links to the scanner.
Quality & Balance Sheet
Momentum & Trend
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -3.15 | -4.47 – -1.87 | 143 | -154.1% | 12 |
| 12/31/2027 | -3.55 | -5.00 – -2.18 | 125 | -12.6% | 12 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -8.6%
- More than 10% revenue growth is expected for the coming year 51.2%
- Share count grows by less than 3% a year 7.6%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -96.5%
- Gross margin at 40% or higher and without meaningful erosion 91.6%
- Goodwill from acquisitions does not grow faster than revenue 0.0%
- Net debt below twice EBITDA 360 m net cash
- Operating cash flow covers the profits of the last three years 198 m
- Return on capital at 15% or higher, or up versus two years ago -22.8%
- Insiders hold at least 10% or are net buyers 1.2%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
1/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 4.1%
- Exp. sales growth 3Y > 5% -0.4%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% -0.4%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 3
- Max. EBIT decline < 50% 100.0%
- Return on equity > 15% -14.7%
- ROCE > 15% -22.8%
- Expected return > 10% -7.9%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 16, 2026 | Deshaies Raymond Joseph | Director | Other | 10,302 | 0.00 | – |
| Jun 16, 2026 | Feigal Ellen | Director | Other | 10,302 | 0.00 | – |
| Jun 16, 2026 | Klencke Barbara | Director | Other | 10,302 | 0.00 | – |
| Jun 16, 2026 | Gustafson Kurt A | Director | Other | 10,302 | 0.00 | – |
| Jun 16, 2026 | Montgomery Alan Bruce | Director | Other | 10,302 | 0.00 | – |
| Jun 16, 2026 | Ranieri Richard J | Director | Other | 10,302 | 0.00 | – |
| Jun 16, 2026 | Simpson Todd E | Director | Other | 10,302 | 0.00 | – |
| Jun 16, 2026 | Gorman Kevin Charles | Director | Other | 10,302 | 0.00 | – |
The company
About the Company
Xencor, Inc., ein biopharmazeutisches Unternehmen in der klinischen Phase, konzentriert sich auf die Entdeckung und Entwicklung technisch entwickelter Antikörper zur Behandlung von Krebs und Autoimmunerkrankungen.
- CEO Insider Trades (12 Mo.)
- selling own stock
- Employees
- 260
- Headquarters
- Pasadena, CA
- Address
- 465 North Halstead Street, 91107 Pasadena, United States
- Phone
- 626 305 5900
- Website
- xencor.com
- IPO Date
- 12/03/2013
- ISIN
- US98401F1057
Management
| Name | Title | Birth Year |
|---|---|---|
| Bassil I. Dahiyat Ph.D. | Co-Founder, CEO, President & Director | 1970 |
| Bart Jan Cornelissen | Senior VP & CFO | 1978 |
| John R. Desjarlais Ph.D. | Executive VP of Research & Chief Scientific Officer | 1964 |
| Celia E. Eckert J.D. | Senior VP, General Counsel & Corporate Secretary | 1972 |
| Charles Liles | Associate Director and Head of Corporate Communications & Investor Relations | – |
| Jennifer Sandoz | Senior VIce President of Human Resources | – |
| Kirk Rosemark RAC | Senior Vice President of Regulatory Affairs & Quality Assurance | 1965 |
| Eric P. Kowack | Senior Vice President of Program Leadership & Alliance Management | – |
| Dane Vincent Leone C.F.A. | Executive VP & Chief Strategy Officer | – |
| Mark Osterman M.D. | Senior Vice President of Clinical Development (Autoimmune) | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
- 08/05/2026 Xencor Inc (XNCR): Results of Operations and Financial Condition; Financial Statements and Exhibits SEC ↗
- 07/29/2026 Xencor Inc (XNCR): Entry into a Material Definitive Agreement; Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Exhibits SEC ↗
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.